Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

World-first gene therapy for cystic fibrosis targets lung stem cells?

21.10.2002


PhD student Maria Limberis inspects a CF mouse


The genetically – inherited disease cystic fibrosis causes severe, unrelenting lung disease in children and adults worldwide. Approximately 1 in 2,500 infants are born with this disease and only half survive past 30 years of age.

Now, researchers from the Women’s and Children’s Hospital, Adelaide have developed a novel system of gene therapy for lungs affected by cystic fibrosis, involving a natural compound found in our lungs which ’conditions’ lung airways to allow cells to take up the therapeutic gene.

Our lungs have developed highly effective ways to protect us from allergens, irritants, dust, viruses and other foreign particles. But according to principal medical scientist in Pulmonary Medicine, Dr David Parsons these defences also hinder effective gene therapy in our lungs.



"Using a mouse model of cystic fibrosis Maria Limberis, a PhD student in our lab, has helped us develop a system to briefly overcome these defences. As the cells lining the mouse nose behave in much the same way as human lung cells – this enables us to use the nose airways in mice to easily develop and test out gene therapy treatments.

"By instilling a single dose of a detergent found naturally in low amounts in our lungs, we are able to ’condition’ cells to take up the gene needed to treat cystic fibrosis.

" Viruses are very good at transferring their genetic material into cells and we make use of this by getting useful parts of an inactive and highly-modified human immunodeficiency virus type 1 (HIV 1) to safely transfer the cystic fibrosis gene into cells. We use this modified HIV because it is one of the few viruses that can give long-lasting gene transfer," Dr Parsons says.

Using this system, the research team has shown, for the first time in a living animal, that long-lived gene therapy for cystic fibrosis is possible. Not only do the airway cells take up the correcting gene, but these cells also show substantial recovery from the cystic fibrosis defect for, so far, at least 110 days.

"Airway cells are replaced every three months so our findings are particularly exciting because they imply we are in fact targeting airway stem cells through this approach - some of the therapeutic gene must have been passed on from these parent stem cells to their daughter cells for the effect to persist beyond three months," Dr Parsons says.

Research funding is now being sought to establish the most effective dose and timing for giving the detergent together with rigorous safety checks on the highly modified HIV-1 based virus particle used for the gene transfer.

Another senior member of the team, molecular biologist Dr Don Anson, explains, "Last year we published a method which vastly increases the safety with which HIV-1 can be modified and used to transfer genes without causing disease.

"We are now working to further improve on this method in order that patients and their families will feel totally confident to eventually take part in human trials of this gene therapy for cystic fibrosis," Dr Anson says.


The work from this research is to be published in Human Gene Therapy, volume 13 #16 on October 20.

Members of the Research Team are:
Dr David Parsons (Medical Scientist, Pulmonary Medicine)
Dr Don Anson (Senior Molecular Biologist, Chemical Pathology)
Dr Maria Fuller (Molecular Biologist, Chemical Pathology)
Ms Maria Limberis (PhD student, Pulmonary Medicine)

Dr Edna Bates | EurekAlert!
Further information:
http://www.wch.sa.gov.au/

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>